BGM Group (BGM) Fair Value & Analysis
Healthcare · US · Market cap $77.9M
BGM Group
BGM · US
Fair value as of: Jul 14, 2026
From 2 valuation models · updated today
Fair value updated Jul 14, 2026 — revised from $1.06 to $0.1100 (−89.6%) since Jun 24, 2026. Share price −9.8% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.2612 – $11.75 · fair‑value band $0.0900 – $0.1200 · the $0.3381 price screens above the $0.1100 fair value. As of Jul 14, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
BGM Group (BGM) currently trades at $0.3381, while our model-based Fair Value estimate is $0.1100 — implying the stock looks roughly 67.5% overvalued today. We read business quality at 34/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $29.9M. Revenue grew 13.9% year over year. It earns a return on equity of -16.5%. The balance sheet holds a net cash position of $9.8M. Fundamentals as of Jul 14, 2026
Our scenario range runs from $0.0900 (bear case) to $0.1200 (bull case); at $0.3381, the current price sits above that range. For context, the median of 10 Healthcare peers we cover trades at -44% fair-value upside — at -67%, BGM screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 14, 2026. TTM = trailing twelve months.
About the company
BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; …
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
BGM Group reported revenue of $25.1M in FY2024 versus $50.0M in FY2020, a compound −15.8%/yr. Reported net income was −$1.4M in FY2024.
Is BGM fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 14, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,416 | ₹1,466 | +4% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,086 | ₹515.38 | -53% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,291 | ₹1,053 | -18% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BGM Group (BGM) undervalued?
What is the fair value of BGM?
What is the quality score of BGM?
What is the revenue of BGM Group (BGM)?
What is the net profit margin of BGM?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full BGM Group analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.